Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Lipitor Lawsuit News: Bernstein Liebhard LLP Notes Pfizer, Inc. Opposition to Creation of Multidistrict Litigation for Lipitor Lawsuits Involving Diabetes Allegations

November 8, 2013

The Firm is evaluating potential Lipitor lawsuits that allege an association between the use of Lipitor and diabetes.

New York, New York (PRWEB) November 08, 2013

As Lipitor lawsuit (http://www.thelipitorlawsuit.com/) claims involving allegations that the cholesterol-lowering medication caused users to develop type 2 diabetes continue to mount in federal courts throughout the U.S., Bernstein Liebhard LLP notes that Pfizer, Inc. has voiced opposition to the creation of a multidistrict litigation for all federally-filed lawsuits involving Lipitor diabetes allegations. In a Response filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) on November 1st, Pfizer argued that such a process would delay the litigation. According to court documents, this is contrary to the position of plaintiffs who recently petitioned the JPML for the establishment of such a proceeding, and argue that a multidistrict litigation would provide the most efficient means of moving lawsuits involving allegations of Lipitor and diabetes through the courts. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))

“The number of Lipitor lawsuits is growing rapidly, and our Firm hears from alleged victims of Lipitor and diabetes on a regular basis. We anticipate this being a large litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit consultations to anyone who may have developed Type 2 diabetes due to the use of this statin medication.

Lipitor and Diabetes Allegations

According to Pfizer’s Response, more than 100 lawsuits involving Lipitor diabetes allegations are now pending in federal courts throughout the country. In October, plaintiffs in Lipitor lawsuits filed their second request for a consolidated litigation, after the JPML rejected a request filed in April. In refusing the plaintiffs’ first petition, the Panel asserted that there were not enough claims pending to warrant the creation of a multidistrict litigation. But at that time, just two dozen cases had been filed. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2459 (JPML))

According to Bernstein Liebhard LLP, a multidistrict litigation like the one proposed for Lipitor lawsuits would allow all federally-filed claims to undergo coordinated pretrial discovery and motions practice. The aim of such a proceeding is to preserve the resources of the court, parties and witnesses, and to avoid duplicative discovery and inconsistent court rulings across a large number of cases involving similar allegations of fact.

According to court records, plaintiffs proposed in their second petition that the federal Lipitor litigation be established in U.S. District Court, District of South Carolina, where at least 14 Lipitor lawsuits are pending and are being coordinated in an informal manner. Additional court filings indicate that a number of similar Lipitor lawsuits have been consolidated in U.S. District Court, Southern District of Illinois, for the purposes of discovery and other pretrial proceedings. (Hines v.Pfizer Inc., No. 13-404, S.D. Ill.)

Court filings indicate that the Lipitor litigation has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) ordered Pfizer, Inc. to add new warnings to the Lipitor label regarding an increased risk of new-onset diabetes in patients who took the cholesterol-lowering statin. The FDA took action after a study published in JAMA: Internal Medicine reported that post-menopausal women treated with the statin may be at an increased risk for developing the disease.*

Alleged victims of Lipitor and diabetes may be eligible for compensation for their injury-related damages, including medical expenses, lost wages, pain and suffering, and more. Learn More about potential Lipitor side effects at Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.

*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.thelipitorlawsuit.com/

For the original version on PRWeb visit: http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes-lawsuit/prweb11316820.htm


Source: prweb